Loading
HER3 is a cousin of HER2 that cancers use as an escape route when HER2 or EGFR are blocked. This dossier gathers the 8 products (2 approved), 92 trials, 0 pathways and 1 resistance route in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Neuregulin (NRG1) ligand; NRG1 fusions are rare drivers targeted by zenocutuzumab. Broadly expressed across breast, lung, and colorectal cancers.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 80-90% | IHC, any expression | EGFR-mutant NSCLC in HERTHENA-Lung01 | Wikipedia |
| Triple-negative breast cancer | 50-70% | IHC, any expression | Wikipedia | |
| HR-positive / HER2-negative breast cancer | 50-70% | IHC, any expression | Wikipedia | |
| Gallbladder cancer | 7-12% | Mutation (amplification rarer) | 11.8% of 57 (Li 2014, a significantly mutated gene); mutation in 16 of 244 samples, 6.6%, and amplification in 12 of 244, 4.9%, in cBioPortal gbc_mskcc_2022; absent from the 21 Chilean tumours in Narayan 2019. | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Phase 3 | Phase 2 |
|---|---|---|---|
| ADC 4 | - | ||
| Antibody 2 | - | ||
| Bispecific ADC 1 | - | - | |
| Bispecific antibody 1 | - | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
BL-B01D1-307 NCT06382142 | 3 | Positive | Previously treated locally advanced or metastatic TNBC: izalontamab brengitecan vs chemotherapy | PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026). | |
PANKU-Esophagus01 (BL-B01D1-305) NCT06304974 | 3 | Positive | Recurrent or metastatic oesophageal squamous cell carcinoma after PD-(L)1 inhibitor plus platinum chemotherapy: izalontamab brengitecan vs chemotherapy of physician's choice | OS and PFS significantly improved at interim analysis; numbers per ASCO 2026 presentation. | |
HER2CLIMB-05 NCT05132582 | 3 | Positive | First-line HER2+ metastatic breast cancer after induction with taxane + trastuzumab + pertuzumab: maintenance tucatinib + HP vs placebo + HP | PFS 24.9 vs 16.3 months, HR 0.64. | |
HERTHENA-Lung02 NCT05338970 | 3 | Mixed | EGFR-mutant NSCLC after third-generation TKI: patritumab deruxtecan vs platinum chemotherapy | PFS HR 0.77 (5.8 vs 5.4 months); OS not significant; BLA withdrawn. | |
PATINA NCT02947685 | 3 | Positive | Hormone receptor-positive, HER2-positive metastatic breast cancer after induction chemotherapy with anti-HER2 therapy: maintenance anti-HER2 therapy and endocrine therapy with or without palbociclib | Palbociclib added to maintenance anti-HER2 and endocrine therapy lengthened progression-free survival. | |
| 3 | Completed | A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation | - | ||
KRISTINE NCT02131064 | 3 | Negative | Stage II to III HER2-positive breast cancer: neoadjuvant trastuzumab emtansine plus pertuzumab vs docetaxel, carboplatin, trastuzumab and pertuzumab | Pathological complete response 44.4% (T-DM1 + pertuzumab) vs 55.7% (TCHP); more locoregional progression before surgery with T-DM1. | |
TRAIN-2 NCT01996267 | 3 | Positive | Stage II to III HER2-positive breast cancer: neoadjuvant carboplatin and paclitaxel with trastuzumab and pertuzumab, with or without three cycles of anthracycline first | Pathological complete response 67% without anthracycline vs 68% with; 3-year event-free survival 93.5% vs 92.7%. | |
APHINITY NCT01358877 | 3 | Positive | Adjuvant HER2+ early breast cancer: pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy | 8-year iDFS HR 0.78; node-positive absolute +4.9%. | |
CLEOPATRA NCT00567190 | 3 | Positive | First-line HER2+ metastatic breast cancer: pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel | OS 57.1 vs 40.8 months, HR 0.69. | |
| 3 | Recruiting | An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04). | - | ||
| 3 | Active | A Phase III Multicenter, Randomized, Open-label, Active-Controlled Study of SHR-A1811 With or Without Pertuzumab Versus Trastuzumab, Pertuzumab and Docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer | - | ||
| 3 | Active | A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study | - | ||
| 3 | Recruiting | A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 for Injection Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer | - | ||
| 3 | Recruiting | A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) | - | ||
| 3 | Active | A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy | - | ||
| 3 | Active | A Phase III Randomized Controlled Trial to Compare BL-B01D1 With Physician's Choice of Chemotherapy (Last Line) in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Previously Treated With PD-1/PD-L1 Monoclonal Antibody and at Least Two Lines of Chemotherapy (at Least One Line of Platinum-based Chemotherapy) | - | ||
| 3 | Active | A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure | - | ||
| 3 | Recruiting | A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer | - | ||
| 3 | Active | A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy | - | ||
| 3 | Recruiting | A Phase III Randomized Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | - | ||
| 3 | Planned | A Phase III Randomized Controlled Clinical Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) | - | ||
| 3 | Recruiting | A Randomized Controlled Phase III Clinical Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer | - | ||
| 3 | Active | A Randomized, Open-label, Multicenter Phase III Study of SHR-A1811 Compared to Docetaxel+Carboplatin+Trastuzumab+Pertuzumab as a Neoadjuvant Therapy for the Initial Treatment of Early-stage or Locally Advanced HER2-positive Breast Cancer | - | ||
| 3 | Active | A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer | - | ||
| 3 | Active | Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer | - | ||
| 3 | Recruiting | A Multicenter, Randomized, Open-label, Phase III Study to Compare the Efficacy and Safety of YL202 and Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | - | ||
| 3 | Active | EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | - | ||
| 3 | Planned | A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer | - | ||
The Sagittarius Trial NCT06490536 | 3 | Recruiting | A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients | - |
Mutation of the cysteine that osimertinib binds covalently; abolishes drug binding while EGFR stays active.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"HER3" OR ABSTRACT:"HER3" OR TITLE:"ERBB3" OR ABSTRACT:"ERBB3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HER3, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/her3.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/her3.json. Licence CC BY-NC 4.0.